Disease · EFO_0801077
cystic fibrosis-related diabetes
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. cystic fibrosis-related diabetes. Diseases, record EFO_0801077. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0801077
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- cystic fibrosis-related diabetes
- Open Targets ID
- EFO_0801077
- Other names
- CF-related diabetes, CFRD
- Highest stage of its drugs
- Phase 3, for 6 of its 17 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs17
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| REPAGLINIDE | CHEMBL1272 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| IVACAFTOR | CHEMBL2010601 | Small molecule | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ELEXACAFTOR | CHEMBL4298128 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN ASPART | CHEMBL1201496 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN DETEMIR | CHEMBL2104391 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TEZACAFTOR | CHEMBL3544914 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| EMPAGLIFLOZIN | CHEMBL2107830 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SEMAGLUTIDE | CHEMBL2108724 | Protein | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SITAGLIPTIN | CHEMBL1422 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 17
See all 17 drugsTargets59
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CFTR | Cystic fibrosis transmembrane conductance regulator | 4 | Cystic fibrosis transmembrane conductance regulator activator; Cystic fibrosis transmembrane conductance regulator positive modulator; Cystic fibrosis transmembrane conductance regulator stabiliser | Phase 3 | https://conductscience.org/library/genes/1080 | Drugs and targets |
| INSR | Insulin receptor | 3 | Insulin receptor agonist | Phase 3 | https://conductscience.org/library/genes/3643 | Drugs and targets |
| GLP1R | Glucagon-like peptide 1 receptor | 2 | Glucagon-like peptide 1 receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/2740 | Drugs and targets |
| ABCC8 | Sulfonylurea receptor 1, Kir6.2 | 1 | Sulfonylurea receptor 1, Kir6.2 blocker | Phase 3 | https://conductscience.org/library/genes/6833 | Drugs and targets |
| COXFA4 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/4697 | Drugs and targets |
| COXFA4L2 | Mitochondrial complex I (NADH dehydrogenase) | 1 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | Phase 2 | https://conductscience.org/library/genes/56901 | Drugs and targets |
| DPP4 | Dipeptidyl peptidase 4 | 1 | Dipeptidyl peptidase IV inhibitor | Phase 2 | https://conductscience.org/library/genes/1803 | Drugs and targets |
| GHR | Growth hormone receptor | 1 | Growth hormone receptor agonist | Phase 1 | https://conductscience.org/library/genes/2690 | Drugs and targets |
| GPD2 | Glycerol-3-phosphate dehydrogenase, mitochondrial | 1 | Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor | Phase 2 | https://conductscience.org/library/genes/2820 | Drugs and targets |
| KCNJ11 | Sulfonylurea receptor 1, Kir6.2 | 1 | Sulfonylurea receptor 1, Kir6.2 blocker | Phase 3 | https://conductscience.org/library/genes/3767 | Drugs and targets |
1 to 10 of 59
See all 59 targetsTrials17
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04599465 | A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF) | Phase 3 | 69 | 2023-08-03 | Cystic Fibrosis | ELEXACAFTOR, IVACAFTOR, TEZACAFTOR | Its record names the disease | ClinicalTrials.gov |
| NCT02496780 | The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients | Phase 2/3 | 65 | 2025-03-17 | Cystic Fibrosis | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT00763412 | Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis | Not applicable | 31 | 2017-06-05 | Cystic Fibrosis Related Diabetes, Pancreatic Insufficiency | REPAGLINIDE | Its record names the disease | ClinicalTrials.gov |
| NCT01879228 | Effect of Chronic Incretin-based Therapy in Cystic Fibrosis | Not applicable | 26 | 2022-02-09 | Cystic Fibrosis, Pancreatic Insufficiency | SITAGLIPTIN | Its record names the disease | ClinicalTrials.gov |
| NCT05788965 | Semaglutide in CFRD | Phase 2/3 | 8 | 2026-01-21 | Cystic Fibrosis, Cystic Fibrosis-related Diabetes | SEMAGLUTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00803179 | Growth Hormone Therapy for Wasting in Cystic Fibrosis | Phase 1 | 5 | 2013-01-15 | Cystic Fibrosis | SOMATROPIN | Its record names the disease | ClinicalTrials.gov |
| NCT00072904 | Diabetes Therapy to Improve BMI and Lung Function in CF | Phase 3 | 108 | Cystic Fibrosis, Diabetes Mellitus | INSULIN ASPART, REPAGLINIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT01100892 | Cystic Fibrosis - Insulin Deficiency, Early Action | Phase 3 | 100 | Cystic Fibrosis, Diabetes | INSULIN DETEMIR | Its record names the disease | ClinicalTrials.gov | |
| NCT03512119 | Observational Study of Glucose Tolerance Abnormalities in Patient With Cystic Fibrosis Homozygous for Phe 508 Del CFTR Treated by Lumacaftor-Ivacaftor | 55 | Cystic Fibrosis Homozygous for Phe 508 Del CFTR, Glucose Intolerance or Newly Diagnosis Diabetes | IVACAFTOR, LUMACAFTOR | Its record names the disease | ClinicalTrials.gov | ||
| NCT01851694 | Beta-cell Response to Incretin Hormones in Cystic Fibrosis | Not applicable | 45 | Cystic Fibrosis, Pancreatic Insufficiency | DEXTROSE, GLUCAGON-LIKE PEPTIDE 1 | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 17
See all 17 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sitagliptin vs Placebo: deaths from any cause | 0 of 13 | 0 of 13 | 26 | NCT01879228 | Trial comparisons |
| Sitagliptin vs Placebo: serious adverse events | 0 of 13 | 0 of 13 | 26 | NCT01879228 | Trial comparisons |
| Repaglinide vs Placebo: deaths from any cause | 0 of 8 | 0 of 8 | 16 | NCT00763412 | Trial comparisons |
| Repaglinide vs Placebo: serious adverse events | 0 of 8 | 0 of 8 | 16 | NCT00763412 | Trial comparisons |
Papers from its trials6
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0801077
GET https://conductscience.org/api/diseases/v1/EFO_0801077/targets?page=2